| Literature DB >> 34204027 |
Daniel Sur1,2, Shanthi Sabarimurugan3, Shailesh Advani4.
Abstract
BACKGROUND: To evaluate and synthesize the existing evidence of the effects of practicing martial arts by cancer patients and cancer survivors in relation to overall quality of life (QoL) and cancer-related fatigue (CRF).Entities:
Keywords: QOL; cancer; clinical trial; fatigue; martial arts; meta-analysis
Mesh:
Year: 2021 PMID: 34204027 PMCID: PMC8201183 DOI: 10.3390/ijerph18116116
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1PRISMA flow diagram.
Baseline characteristics of the included studies.
| ID | Arms | Number | Age (Years) | Female | Cancer Treatment | ||
|---|---|---|---|---|---|---|---|
| Surgery | Chemotherapy | Radiation | |||||
| Campo 2013 | Tai Chi Chih | 32 | 66.54 (55–89) 1 | 32 (100) | 27 | 19 | 21 |
| Health Education Class | 31 | 65.64 (57–84) 1 | 31 (100) | 28 | 19 | 20 | |
| Chen 2013 | Qigong | 49 | 45.3 (6.3) | 49 (100) | 49 | - | 49 |
| Usual care | 47 | 44.7 (9.7) | 47 (100) | 46 | - | 45 | |
| Chuang 2017 | Qigong | 48 | 55.85 (16.78) | 22 (45) | - | 48 | - |
| Usual care | 48 | 64.54 (15.51) | 19 (40) | - | 48 | - | |
| Irwin 2017 | Tai Chi Chih | 45 | 59.6 (7.9) | 45 (100) | 6 | 18 | 22 |
| Cognitive behavioral therapy for insomnia | 45 | 60.0 (9.3) | 45 (100) | 4 | 21 | 34 | |
| Larkey 2016 | Sham Qigong | 45 | 59.8 (8.93) | 45 (100) | - | - | - |
| Qigong and Tai Chi Easy | 42 | 57.7 (8.94) | 42 (100) | - | - | - | |
| Loh 2014 | Qigong | 32 | 18–65 | 32 (100) | 32 | 23 | 18 |
| Line dance | 31 | 31 (100) | 31 | 23 | 18 | ||
| McQuade 2017 | Qigong/tai chi | 21 | 62.2 (7.4) | 21 (100) | - | - | 21 |
| Waitlist control | 24 | 66.0 (8.4) | 24 (100) | - | - | 24 | |
| Mustian 2004 | Tai Chi Chuan | 11 | 52 (9) | 11 (100) | 21 | 18 | 13 |
| Psychosocial support | 10 | 10 (100) | |||||
| Mustian 2008 | Tai Chi Chuan | 11 | 52 (9) | 11 (100) | 21 | 18 | 13 |
| Psychosocial support | 10 | 10 | |||||
| Oh 2008 | Qigong | 15 | 54 (9) | 12 (80) | - | - | - |
| Usual care | 15 | 12 (80) | - | - | - | ||
| Oh 2009 | Qigong | 79 | 60.1 (11.7) | 48 (61) | - | - | - |
| Usual care | 83 | 59.9 (11.3) | 45 (54) | - | - | - | |
| Sprod 2011 | Tai Chi Chuan | 9 | 54.33 (3.55) 2 | 9 (100) | 9 | 6 | 8 |
| Standard support therapy | 10 | 52.70 (2.11) 2 | 10 (100) | 10 | 3 | 9 | |
| Strunk 2018 | Kyusho Jitsu | 30 | 54.2 (7.8) | 30 (100) | 29 | 14 | 23 |
| Control | 21 | 51.5 (8.4) | 21 (100) | 21 | 15 | 17 | |
| Thongteratham 2015 | Tai Chi Qi Qong | 15 | - | 15 (100) | 15 | 15 | 15 |
| Usual care | 15 | - | 15 (100) | 15 | 15 | 15 | |
| Vanderbyl 2017 | Qigong | 11 | 66.1 (11.7) | 4 (37) | - | - | - |
| standard endurance and strength training | 13 | 63.7 (7.7) | 6 (46) | - | - | - | |
| Zhang 2016 | Tai Chi Chih | 47 | 62.8 | 10 (21) | 47 | - | - |
| Control | 44 | 13 (30) | 44 | - | - | ||
| Zhou 2017 | Tai Chi Chih | 57 | 18–70 | 19 (33) | - | 57 | 57 |
| Control | 57 | 12 (21) | - | 57 | 57 | ||
Values reflect number or mean (standard deviation); 1 median (range); 2 standard error of the mean.
Summary of the included studies.
| ID. | Country | Cancer Type | Timing of Intervention | Type of Treatment | Session, Minutes | Frequency, Times/Week | Period, Week | Outcomes | Time |
|---|---|---|---|---|---|---|---|---|---|
| Campo 2013 | USA | Breast, colorectal, ovarian, cervical/uterine, thyroid, bladder, nasopharyngeal | ≥3 months after TTT 3 | Surgery, radiation, chemotherapy, hormone, other | 60 | 3 | 12 | SF-36 6 | Baseline and 1 week after |
| Chen 2013 | China | Breast | During TTT | Radiation | 60 | 5 | 5–6 | FACT-G, BFI 7 | Baseline, during and at the end of treatment, and 1 and 3 months later. |
| Chuang 2017 | Taiwan | Lymphoma | During TTT | Chemotherapy | 60 | 2 | 10 | EORTC QLQ-C30, BFI 4 | Baseline and 21 days after |
| Irwin 2017 | USA | Breast | ≥ 6 months after TTT | Surgery, radiation and/or chemotherapy | 120 min weekly | 12 | MFSI-SF 9 | Baseline and 2, 3, 6, and 15 months | |
| Larkey 2016 | USA | Breast | 6 months to 5 years after TTT | Surgery, radiation, or chemotherapy | 30 | 5 | 12 | SF-36 | Baseline and 12 and 24 weeks |
| Loh 2014 | Malaysia | Breast | TTT completed | NM | 30 | 2 | 8 | FACT-G 5 | Baseline and 8 weeks |
| McQuade 2017 | USA | Prostate | During TTT | Radiation | 60 | 3 | 6–8 | BFI | Baseline, midway, during the last week of TTT, and 3 months after TTT. |
| Mustian 2004 | USA | Breast | 1 week to 30 months after TTT | NM | 60 | 3 | 12 | FACIT–F 8 | Baseline and 12 weeks after |
| Mustian 2008 | USA | Breast | 1 week to 30 months after TTT | NM | 60 | 3 | 12 | FACIT–F | Baseline and 12 weeks after intervention |
| Oh 2008 | Australia | Breast, ovary, lung, lymphoma, colon | During or completed TTT | Cancer treatment, chemotherapy | 60 | 1 or 2 | 8 | EORTC QLQ-C30 | Baseline and 8 weeks |
| Oh 2009 | Australia | Breast, lung, prostate, colorectal, bowel | During or completed TTT | NM | 90 min weekly | 10 | FACIT–F, FACT-G | Baseline and 10 weeks after intervention | |
| Sprod 2011 | USA | Breast | 1 month to 30 months after TTT | NM | 60 | 3 | 12 | SF-36 | Baseline and 6 and 12 weeks |
| Strunk 2018 | German | Breast | ≥ 6 months after TTT | Not hormone treatment | 90 | 2 | 24 | EORTC QLQ-C30 | Baseline and 12 and 24 weeks |
| Thongteratham 2015 | Thailand | Breast | TTT completed | NM | 60 | 3 | 12 | FACT-G | Baseline and 12 and 24 weeks |
| Vanderbyl 2017 | Canada | NSCLC 1 or GI 2 | During TTT | Chemotherapy | 45 | 2 | 6 | FACT-G | Baseline and 6 weeks |
| Zhang 2016 | China | Lung | During TTT | Chemotherapy | 60 | 3 | 12 | MFSI-SF | Baseline and 43 and 85 days |
| Zhou 2017 | China | Nasopharyngeal carcinoma | During TTT | Chemotherapy | 60 | 5 | 6 | MFSI-SF | Baseline and after treatment |
NM, not mentioned; 1 NSCLC, non-small cell lung cancer; 2 GI, gastrointestinal cancer; 3 TTT, treatment; 4 EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; 5 FACT-G, Functional Assessment of Cancer Therapy—General; 6 SF-36, the Short-Form 36; 7 BFI, the Brief Fatigue Inventory; 8 FACIT-F, Functional Assessment of Chronic Illness Therapy—Fatigue; 9 MFSI-SF, the Multidimensional Fatigue Symptom Inventory—Short Form.
Figure 2Analysis of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30).
Figure A1Results of EORTC QLQ-C30 after sensitivity analysis.
Figure 3Analysis of Functional Assessment of Cancer Therapy—General.
Figure A2Results of FACT-G change after sensitivity analysis.
Figure 4Analysis of the Short-Form 36.
Figure A3Results of SF-36 after sensitivity analysis.
Figure 5Analysis of the Brief Fatigue Inventory.
Figure A4Results of BFI after sensitivity analysis.
Figure 6Analysis of Functional Assessment of Chronic Illness Therapy—Fatigue.
Figure 7Analysis of the multidimensional fatigue symptom inventory-short form.
Figure A5Results of MFSI-SF after sensitivity analysis.
Figure 8Risk of bias summary.
Figure 9Risk of bias graph.